Clinical Trials Browser

Phase 3 × NIH × (225)Ac-DOTA-c(RGDyK) × Clear all

NCT06589804 2026-06-03

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms